methylprednisolone, prednisone
ApprovedSmall molecule
Bristol-Myers Squibbmethylprednisolone, prednisone is one of 37 small molecule programs targeting Kidney Transplant. It is currently in Approved.
3
Indications
5
Total Trials
0
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
476 competitors in Kidney Transplant
#DrugCompanyPhaseTrials
1methylprednisolone, prednisone
Bristol-Myers SquibbApproved
Nulojix
Bristol-Myers SquibbPreclinical
Simulect
NovartisPreclinical
Medrol
PfizerPreclinical
Zemplar
AbbViePreclinical
Sensipar
AmgenPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Radicava
ShionogiPreclinical
Jardiance
Boehringer IngelheimPreclinical
Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Prospective1 trial
Glomerular Disease1 trial
Diarrhea1 trial
Kidney Transplant1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company